In genetic studies in mice, it has also been found that co-deletion of TP53 and PTEN in mouse prostate epithelial cells leads to aggressive prostate cancer and development of CRPC that is newly resistant to androgen deprivation therapy (Shi et al., 2023). Here, TP53 is linked to prostate carcinoma.